{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-009203","form_type":"8-K/A","ticker":"WINT","cik":"0000946486","company_name":"WINDTREE THERAPEUTICS INC /DE/","filed_at":"2025-03-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:06.904456+00:00","generated_at":"2026-05-24T06:16:08.805494+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Windtree signs sourcing deal for Evofem's FDA-approved PHEXXI contraceptive gel","bullets":["License and Supply Agreement makes Windtree sourcing partner for Evofem's PHEXXI (hormone-free vaginal gel).","PHEXXI generated >$19M revenue in FY2024; 96,000 boxes of 12 applicators sold.","Windtree aims to cut manufacturing costs via its contacts, aiding Evofem's global expansion.","Saundra Pelletier is CEO of Evofem and also serves on Windtree's board of directors.","Deal is first step in Windtree's new strategy to become a revenue-generating biotech."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-009203","json":"https://secwatch.observer/filing/0001437749-25-009203.json","markdown":"https://secwatch.observer/filing/0001437749-25-009203.md","text":"https://secwatch.observer/filing/0001437749-25-009203.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/946486/000143774925009203/0001437749-25-009203-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/946486/000143774925009203/wint20250324_8ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T06:16:08.805494+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}